MedTrace Logo

Effect of Lifitegrast 5% on Tear Film Markers

NCT03952481 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-02-16

No results posted yet for this study

Summary

The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.

Conditions

  • Dry Eye
  • Dry Eye Syndromes
  • Dry Eyes Chronic

Interventions

DRUG

Lifitegrast 5% Ophthalmic Solution

Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Christopher Starr, MD · Weill Medical College of Cornell University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952481 on ClinicalTrials.gov